Effect of two oral formulations of cannabidiol on responses to emotional stimuli in healthy human volunteers: pharmaceutical vehicle matters Jose´A. Crippa, Luiz C. Pereira Junior, Livia C. Pereira, Patricia M. Zimmermann, Liberato Brum Junior, Leticia M. Rechia, Isabella Dias, Jaime E. Hallak, Alline C. Campos, Francisco S. Guimaraes, Regina H. Queiroz, Antonio W. Zuardi Brazilian Journal of Psychiatry, 2021, 1-6. Doi : 10.1590/1516-4446-2020-1684 Objective : To compare plasma concentrations of cannabidiol (CBD) following oral administration of two formulations of the drug (powder and dissolved in oil), and to evaluate the effects of these distinct formulations on responses to emotional stimuli in healthy human volunteers. Methods [...]
Lire la suiteNew Insights on Hemp Oil Enriched in Cannabidiol: Decarboxylation, Antioxidant Properties and In Vitro Anticancer Effect Anca Roxana Petrovici, Natalia Simionescu, Andreea Isabela Sandu, Vasile Paraschiv, Mihaela Silion and Mariana Pinteala Antioxidants, 2021, 10, 738. doi : 10.3390/antiox10050738 Abstract : This study aimed to obtain and characterize extracted hemp oil enriched in cannabidiol (CBD) by decarboxylation of cannabidiolic acid (CBDA) and to give new insights into its antioxidant and anticancer effects. Optimization of CBDA decarboxylation in hemp oil was performed, and CBD and CBDA contents and purities were determined by flash chromatography, 1H- and 13C-NMR. The antioxidant properties of CBD-enriched oil were investigated by Fe2+ [...]
Lire la suiteCannabidiol has a unique effect on global brain activity: a pharmacological, functional MRI study in awake mice Aymen H. Sadaka, Ana G. Ozuna1, Richard J. Ortiz, Praveen Kulkarni, Clare T. Johnson, Heather B. Bradshaw, Bruce S. Cushing, Ai‑Ling Li, Andrea G. Hohmann and Craig F. Ferris Journal of Translationnal Medicine, 2021, 19, 220, 1-16. Doi : 10.1186/s12967-021-02891-6 Abstract Background : The phytocannabinoid cannabidiol (CBD) exhibits anxiolytic activity and has been promoted as a potential treatment for post-traumatic stress disorders. How does CBD interact with the brain to alter behavior? We hypothesized that CBD would produce a dose-dependent reduction in brain activity and functional coupling in [...]
Lire la suiteA qualitative and quantitative account of patient’s experiences of ketamine and its antidepressant properties Rachael L. Sumner, Emme Chacko, Rebecca McMillan, Meg J. Spriggs, Christie Anderson, James Chen, Amelia French, SungHun Jung, Akshaya Rajan, Gemma Malpas, John Hay, Rhys Ponton, Suresh D. Muthukumaraswamy and Frederick Sundram Journal of Psychopharmacology, 2021, 1-16 Doi : 10.1177/0269881121998321 Abstract Background : Ketamine is central to one of the most rapidly growing areas of neuroscientific research into novel treatments for depression. Limited research has indicated that the psychedelic properties of ketamine may play a role in its antidepressant effects. Aim : The aim of the current study was to explore the [...]
Lire la suiteEffects of acute cannabidiol administration on anxiety and tremors induced by a Simulated Public Speaking Test in patients with Parkinson’s disease Stephanie Martins de Faria, Daiene de Morais Fabrício, Vitor Tumas, Paula Costa Castro, Moacir Antonelli Ponti, Jaime E.C. Hallak, Antonio W. Zuardi, José Alexandre S. Crippa and Marcos Hortes Nisihara Chagas Journal of Psychopharmacology, 2020, 1–8 doi : 10.1177/0269881119895536 Abstract Background : Cannabidiol (CBD) is one of the main components of Cannabis sativa and has anxiolytic properties, but no study has been conducted to evaluate the effects of CBD on anxiety signs and symptoms in patients with Parkinson’s disease (PD). This study aimed to [...]
Lire la suiteMDMA-assisted therapy for severe PTSD : a randomized, double-blind, placebo-controlled phase 3 study Jennifer M. Mitchell, Michael Bogenschutz, Alia Lilienstein, Charlotte Harrison, Sarah Kleiman6, Kelly Parker-Guilbert7, Marcela Ot’alora G., Wael Garas, Casey Paleos, Ingmar Gorman 11, Christopher Nicholas12, Michael Mithoefer5,9,13, Shannon Carlin, Bruce Poulter 8,9, Ann Mithoefer9, Sylvestre Quevedo2,14, Gregory Wells 14, Sukhpreet S. Klaire, Bessel van der Kolk16, Keren Tzarfaty9, Revital Amiaz17, Ray Worthy18, Scott Shannon, Joshua D. Woolley2, Cole Marta20, Yevgeniy Gelfand21, Emma Hapke, Simon Amar, Yair Wallach, Randall Brown11, Scott Hamilton25, Julie B. Wang5, Allison Coker 1,5, Rebecca Matthews, Alberdina de Boer5, Berra Yazar-Klosinski, Amy Emerson and Rick Doblin Nature Medicine | www.nature.com/naturemedicine, 2021, 1-12. doi : [...]
Lire la suiteTrial of Psilocybin versus Escitalopram for Depression Robin Carhart-Harris, Ph.D., Bruna Giribaldi, B.Sc., Rosalind Watts, D.Clin.Psy., Michelle Baker-Jones, B.A., Ashleigh Murphy-Beiner, M.Sc., Roberta Murphy, M.D., Jonny Martell, M.D., Allan Blemings, M.Sc., David Erritzoe, M.D. and David J. Nutt, M.D.New England Journal of Medicine, 2021, 384, 1402-1411Doi : 10.1056/NEJMoa2032994 Abstract Background Psilocybin may have antidepressant properties, but direct comparisons between psilocybin and established treatments for depression are lacking. Methods In a phase 2, double-blind, randomized, controlled trial involving patients with long-standing, moderate-to-severe major depressive disorder, we compared psilocybin with escitalopram, a selective serotonin-reuptake inhibitor, over a 6-week period. Patients were assigned in a 1:1 ratio to receive [...]
Lire la suitePsilocybin for treatment-resistant depression : fMRI-measured brain mechanisms Robin L Carhart-Harris, Leor Roseman, Mark Bolstridge, Lysia Demetriou, J Nienke Pannekoek, Matthew B Wall, Mark Tanner, Mendel Kaelen, John McGonigle, Kevin Murphy, Robert Leech, H Valerie Curran & David J Nutt Nature, Scientific Reports, 2017, 7, 13187 |1-11 Doi : 10.1038/s41598-017-13282-7 Abstract Psilocybin with psychological support is showing promise as a treatment model in psychiatry but its therapeutic mechanisms are poorly understood. Here, cerebral blood flow (CBF) and blood oxygen-level dependent (BOLD) resting-state functional connectivity (RSFC) were measured with functional magnetic resonance imaging (fMRI) before and after treatment with psilocybin (serotonin agonist) for treatment-resistant depression (TRD). [...]
Lire la suitePsilocybin Delivers ‘Remarkable’ Relief in Severe Depression, Batya Swift Yasgur, Medscape.com, 2020
Psilocybin Delivers 'Remarkable' Relief in Severe Depression Batya Swift Yasgur, MA, LSW Medscape Medical News, November 05, 2020 Psilocybin, the psychedelic compound in "magic mushrooms," rapidly improves symptoms and produces remission in as little as two sessions for patients with major depression, new research suggests. Results of a small randomized trial showed that treatment with psilocybin was associated with a greater than 50% reduction in depressive symptoms in 67% of study participants. In addition, 71% showed improvement at 4-week follow-up, with more than 50% achieving remission. "The finding that the majority of people whom we treated showed efficacy was quite a remarkable and gratifying finding [...]
Lire la suitePsilocybin Matches SSRI for Moderate-to-Severe Depression in Phase 2 Study Sarah Edmonds Medscape Medical News, April 14, 2021 The psychedelic drug psilocybin performed just as well as a widely used antidepressant in easing the symptoms of major depression, and outperformed the selective serotonin reuptake inhibitor (SSRI) on a range of secondary measures, results of a small-scale phase 2 study show. In a 6-week trial that included 59 patients with moderate-to-severe depression, there was no significant difference between the impact of high-dose psilocybin on the study's primary yardstick — the 16-item Quick Inventory of Depressive Symptomatology–Self-Report (QIDS-SR-16) — and that of selective serotonin reuptake [...]
Lire la suite